Michael Ostrach - Dynavax Technologies President
| DVAX Stock | USD 12.36 0.19 1.56% |
President
Mr. Michael S. Ostrach serves as Chief Financial Officer, Senior Vice President, Chief Business Officer of the Company. Mr. Ostrach joined Dynavax in October 2006 as Vice President, Chief Business Officer and General Counsel, and became Principal Financial Officer in September 2013, Chief Financial Officer in March 2015 and Senior Vice President in February 2016. Mr. Ostrach held the position of Dynavaxs General Counsel from October 2006 to September 2015. From 2005 to 2006, he was Chief Operating Officer, Chief Financial Officer and General Counsel at Threshold Pharmaceuticals. From 1997 to 2004, Mr. Ostrach was at Kosan Biosciences, most recently as President and Chief Operating Officer since 2016.
| Age | 72 |
| Tenure | 8 years |
| Address | 2100 Powell Street, EmeryVille, CA, United States, 94608 |
| Phone | 510 848 5100 |
| Web | https://www.dynavax.com |
Dynavax Technologies Management Efficiency
Return On Tangible Assets is likely to drop to -0.0067 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 21.4 M in 2024, whereas Other Assets are likely to drop slightly above 3 M in 2024. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| John Bardi | Intracellular Th | N/A | |
| Robert Davis | Intracellular Th | 73 | |
| Stephen Carey | ANI Pharmaceuticals | 53 | |
| Carol Walker | Lantheus Holdings | 61 | |
| Michael Landine | Alkermes Plc | 70 | |
| Robert Kramer | Emergent Biosolutions | 62 | |
| Mark Neumann | Intracellular Th | 61 | |
| Daniel Barber | Aquestive Therapeutics | 48 | |
| Scott Dreyer | Collegium Pharmaceutical | 52 | |
| David Gaffin | Alkermes Plc | 52 | |
| Richard Lindahl | Emergent Biosolutions | 60 | |
| Peter Boyd | Aquestive Therapeutics | 58 | |
| Atul Saran | Emergent Biosolutions | 51 | |
| Sean Kirk | Emergent Biosolutions | 45 | |
| Adam Havey | Emergent Biosolutions | 53 | |
| John Condon | Intracellular Th | N/A | |
| Juan Sanchez | Intracellular Th | 53 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Etienne Montagut | Lantheus Holdings | 49 | |
| Katherine Strei | Emergent Biosolutions | 62 | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
Management Performance
| Return On Equity | 0.0318 | ||||
| Return On Asset | -0.0038 |
Dynavax Technologies Leadership Team
Elected by the shareholders, the Dynavax Technologies' board of directors comprises two types of representatives: Dynavax Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dynavax. The board's role is to monitor Dynavax Technologies' management team and ensure that shareholders' interests are well served. Dynavax Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dynavax Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Riccardo Manetti, Business President | ||
| Eric Frings, Site VP | ||
| Robert Janssen, Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs | ||
| David Novack, Sr. VP of Operations and Quality | ||
| Robert MD, Medical Development | ||
| Donn Casale, Senior Officer | ||
| Nicole Arndt, Sr Relations | ||
| Kelly MacDonald, Senior CFO | ||
| Paul Cox, VP Communications | ||
| Dong Yu, Senior Research | ||
| Ryan Spencer, Interim Co-President Co-Principal Executive Officer | ||
| John Slebir, Senior Counsel | ||
| Jeff Coon, CHRO Administration | ||
| Kelly CPA, Senior CFO | ||
| Justin Burgess, Principal Controller | ||
| Michael Ostrach, Principal Financial Officer, Vice President General Counsel, Chief Business Officer | ||
| Meg Smith, VP Operations | ||
| Todd Lopeman, Senior Operations |
Dynavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dynavax Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0318 | ||||
| Return On Asset | -0.0038 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 1.09 B | ||||
| Shares Outstanding | 131.46 M | ||||
| Shares Owned By Insiders | 0.33 % | ||||
| Shares Owned By Institutions | 99.67 % | ||||
| Number Of Shares Shorted | 18.84 M | ||||
| Price To Earning | 6.95 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.